Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (402)
NICE advice (1)
Quality standard (10)
Guidance programme
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 51 to 75 of 413
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Benralizumab with corticosteroids for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis ID6266
Technology appraisal guidance
TBC
Bevacizumab gamma for treating wet age-related macular degeneration [ID6320]
Technology appraisal guidance
11 December 2024
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal guidance
20 February 2019
Bimatoprost implant for treating open angle glaucoma or ocular hypertension in people who are unsuitable for topical treatments [ID6180]
Technology appraisal guidance
TBC
Bimekizumab for treating moderate to severe hidradenitis suppurativa [ID6134]
Technology appraisal guidance
20 November 2024
Bipolar disorder: assessment and management (extraordinary review)
NICE guideline
TBC
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease [ID6405]
Technology appraisal guidance
26 March 2025
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405
Health technology evaluation
TBC
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768]
Technology appraisal guidance
TBC
Breast cancer guidelines
NICE guideline
TBC
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334]
Technology appraisal guidance
TBC
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
Technology appraisal guidance
TBC
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
7 August 2024
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Technology appraisal guidance
5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Technology appraisal guidance
TBC
Cardiometabolic disease prevention and treatment guidelines
NICE guideline
TBC
Cardiovascular risk assessment and lipid modification
Quality standard
23 July 2025
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
30 April 2025
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
Highly specialised technology
13 November 2024
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure
NICE guideline
TBC
Previous page
1
2
Current page
3
4
5
…
17
Page
3
of
17
Next page
Results per page
10
25
50
All
Back to top